title: Clinical Effectiveness of Intermittent Infusion Hemodiafiltration Using Backfiltration of Ultrapure Dialysis Fluid Compared with Predilution On-Line Hemodiafiltration.
abstract: In conventional hemodialysis (HD) treatment, excessive water removal sometimes induces a rapid drop in blood pressure. Intermittent infusion hemodiafiltration (I-HDF) has been developed to improve patients' peripheral circulation by repeated intermittent infusion during HD treatment.
  
  
  
  A prospective, multicenter, parallel group comparative trial examined the clinical effectiveness of I-HDF compared with predilution on-line HDF (pre-HDF), the most popular on-line HDF therapy in Japan. Patients were allocated to 2 groups after matching for age (± 5 years), dry weight (± 5 kg), and presence/absence of diabetes. After informed consent was obtained, 36 patients (18 pairs) participated in the trial. The results showed no difference in clinical condition or quality of life (QOL) scores between the 2 therapy groups. The rate of reduction in systolic blood pressure initially showed no difference between the groups, but decreased slightly as the trial proceeded after changing from HD therapy. There was also no difference in the incidence rate of treatments initially, although this significantly decreased in both groups as the trial proceeded. Rates of β2-microglobulin removal were significantly higher in the pre-HDF group than in the I-HDF group. At the same time, the amount of albumin leakage during treatment was significantly greater in the pre-HDF group. Key Messages: The clinical condition and QOL of patients receiving I-HDF was not inferior to those receiving pre-HDF. Pre-HDF demonstrated a significantly higher removal rate of middle- and larger-molecular-weight solutes and higher albumin leakage compared with I-HDF.
authors.forename: Michio
authors.initials: M
authors.lastname: Mineshima
authors.forename: Kei
authors.initials: K
authors.lastname: Eguchi
authors.forename: Kanji
authors.initials: K
authors.lastname: Shishido
authors.forename: Susumu
authors.initials: S
authors.lastname: Takahashi
authors.forename: Tsukasa
authors.initials: T
authors.lastname: Kubo
authors.forename: Hiroshi
authors.initials: H
authors.lastname: Kawaguchi
authors.forename: Kouzo
authors.initials: K
authors.lastname: Shitomi
authors.forename: Keigo
authors.initials: K
authors.lastname: Shibagaki
authors.forename: Kiichi
authors.initials: K
authors.lastname: Suga
authors.forename: Hirotomo
authors.initials: H
authors.lastname: Nagao
authors.forename: Mikihiko
authors.initials: M
authors.lastname: Takada
authors.forename: Masahiro
authors.initials: M
authors.lastname: Taoka
authors.forename: Takashi
authors.initials: T
authors.lastname: Sato
mesh_terms: D000328:Adult; D000368:Aged; D000418:Albumins / Q000032:analysis; D001794:Blood Pressure; D015314:Dialysis Solutions; D005260:Female; D017583:Hemodiafiltration / Q000379:methods* / Q000592:standards; D006801:Humans; D008297:Male; D008722:Methods; D008875:Middle Aged; D008970:Molecular Weight; D011788:Quality of Life; D016896:Treatment Outcome
chemical_list: D000418:Albumins; D015314:Dialysis Solutions